Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
06/16/2021 - 04:05 PM
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Tuesday, August 10, 2021.
Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 5:00 p.m. Eastern Time on August 10, 2021. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 1650599. A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/ .
The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until August 10, 2022.
About Bioventus Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com , and follow the Company on LinkedIn and Twitter . Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke/ICRInvestor.relations@bioventus.com
Media Contact: Thomas Hill 919-474-6715thomas.hill@bioventusglobal.com
BVS Rankings
#4902 Ranked by Stock Gains
BVS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
About BVS
bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat